Lipella Pharma Announces Top Line Results In Phase 2A Trial Of LP-10 For Hemorrhagic Cystitis

RTTNews | 933天前
Lipella Pharma Announces Top Line Results In Phase 2A Trial Of LP-10 For Hemorrhagic Cystitis

(RTTNews) - Biotechnology company Lipella Pharmaceuticals Inc. (LIPO) announced top line results for its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for Hemorrhagic Cystitis, a rare but highly morbid disease for which there are currently no FDA approved treatments.

The LP-10 Phase 2a clinical trial was a multi-center, dose-escalation study, which recruited 13 subjects with moderate to severe refractory hemorrhagic cystitis. These subjects were treated with up to two courses of LP-10 intravesical bladder instillations.

The top line results indicated that all subjects tolerated LP-10 instillations and completed the study without report of product related serious adverse events. LP-10 pharmacokinetic analysis also demonstrated short duration of systemic uptake. There were also decreased hematuria, decreased cystoscopic bleeding and ulceration sites and improved patients' urinary symptoms.

Further, the responder analysis noted complete response in 3 subjects, partial response in 7 subjects and no response in 3 subjects.

As it next step, the company said it will communicate with the U.S. Food and Drug Administration (FDA) on the study's results and the pathway forward to seeking regulatory approval for LP-10. If approved, it will be a first-in class treatment for the cancer survivor community with hemorrhagic cystitis.

For More Such Health News, visit rttnews.com

read more
U.S. Construction Spending Unexpectedly Sees Further Downside In June

U.S. Construction Spending Unexpectedly Sees Further Downside In June

The Commerce Department released a report on Friday unexpectedly showing a continued decrease by U.S. construction spending in the month of June. The report said construction spending fell by 0.4 percent to an annual rate of $2.136 trillion in June after sliding by 0.5 percent to a revised rate of $2.144 trillion in May.
RTTNews | 1小時13分鐘前
U.S. Consumer Sentiment Improves Marginally Less Than Previously Estimated In July

U.S. Consumer Sentiment Improves Marginally Less Than Previously Estimated In July

Revised data released by the University of Michigan on Friday showed consumer sentiment in the U.S. improved marginally less than previously estimated in the month of July. The University of Michigan said its consumer sentiment index for July was downwardly revised to 61.7 from a preliminary reading of 61.8. Economists had expected the index to be upwardly revised to 62.0.
RTTNews | 1小時17分鐘前
U.S. Manufacturing Index Unexpectedly Dips To Nine-Month Low In July

U.S. Manufacturing Index Unexpectedly Dips To Nine-Month Low In July

Manufacturing activity in the U.S. unexpectedly contracted at a slightly faster rate in the month of July, according to a report released by the Institute for Supply Management on Friday. The ISM said its manufacturing PMI edged down to 48.0 in July after inching up to 49.0 in June with a reading below 50 indicating contraction.
RTTNews | 1小時19分鐘前
Eurozone Inflation Steady At 2% ECB Target

Eurozone Inflation Steady At 2% ECB Target

Euro area consumer price inflation was unchanged at the European Central Bank's 2 percent target in July, easing the pressure for more easing. The harmonized index of consumer prices increased 2.0 percent year-on-year in July, the same rate of increase as seen in June. Inflation was forecast to ease marginally to 1.9 percent.
RTTNews | 2小時6分鐘前
Bay Street Likely To Open On Weak Note

Bay Street Likely To Open On Weak Note

Canadian shares are set to open on a negative note on Friday as U.S. President Donald Trump's announcement of fresh tariffs on Canada and several other countries has hurt investor sentiment across global markets.
RTTNews | 3小時26分鐘前